Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo

World Health Organization. Malaria. Geneva, Switzerland: WHO. http://www.who.int/topics/malaria/en/ [accessed September 2007]. Kiszewski, 2007, Estimated global resources needed to attain international malaria control goals, Bull World Health Organ, 85, 623, 10.2471/BLT.06.039529 Greenwood, 2005, Malaria, Lancet, 365, 1487, 10.1016/S0140-6736(05)66420-3 Sharma, 2007, Battling the malaria iceberg with chloroquine in India, Malar J, 6, 1, 10.1186/1475-2875-6-105 Bonington, 1990, Fatal quinine cardiotoxicity in the treatment of falciparum malaria, Trans R Soc Trop Med Hyg, 90, 305, 10.1016/S0035-9203(96)90264-3 White, 2007, Cardiotoxicity of antimalarial drugs, Lancet Infect Dis, 7, 549, 10.1016/S1473-3099(07)70187-1 Dalençon, 1997, Atovaquone and rifabutine-loaded nanocapsules: formulation studies, Int J Pharm, 153, 127, 10.1016/S0378-5173(97)00076-8 Sordet, 1998, Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis, Parasite, 5, 223, 10.1051/parasite/1998053223 Pinto-Alphandary, 2000, Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications, Int J Antimicrob Agents, 13, 155, 10.1016/S0924-8579(99)00121-1 Heurtault, 2001, The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro, Ann Trop Med Parasitol, 95, 529, 10.1080/00034983.2001.11813665 Cauchetier, 2003, Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis, Ann Trop Med Parasitol, 97, 259, 10.1179/000349803235001840 Mosqueira, 2004, Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice, Antimicrob Agents Chemother, 48, 1222, 10.1128/AAC.48.4.1222-1228.2004 Losa, 1993, Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol, Pharm Res, 10, 80, 10.1023/A:1018977130559 Guterres, 1995, Poly(d,l-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration, Pharm Res, 12, 1, 10.1023/A:1016208125979 Rodrigues, 1994, The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice, Ann Trop Med Parasitol, 45, 223 Durand, 1997, Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model, Int J Parasitol, 27, 1361, 10.1016/S0020-7519(97)00124-0 Cruz, 2006, Diffusion and mathematical modeling of release profiles from nanocarriers, Int J Pharm, 313, 198, 10.1016/j.ijpharm.2006.01.035 Leite, 2007, Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices, Life Sci, 80, 1327, 10.1016/j.lfs.2006.12.019 Soppimath, 2001, Biodegradable polymeric nanoparticles as drug delivery devices, J Control Release, 70, 1, 10.1016/S0168-3659(00)00339-4 Gupta, 2007, Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain, J Pharm Pharmacol, 59, 935, 10.1211/jpp.59.7.0004 Fessi H, Devissaguet JP, Puisieux F. Procédé de préparation dês systémes colloidaux dispersibles d’une substance sous forme de nanocapsules. European Patent 1988: 0274961 A1. Pedroni, 2006, Plasmodium berghei: development of as irreversible experimental malaria model in Wistar rats, Exp Parasitol, 113, 193, 10.1016/j.exppara.2005.12.017 Wilcox, 1960 Chmurzynski, 1997, High-performance liquid chromatographic determination of quinine in rat biological fluids, J Chromatogr B Biomed Sci Appl, 693, 423, 10.1016/S0378-4347(97)00074-1 Rowland, 1995 Iyer, 1999, In vitro characterization of erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics, J Pharmacokinet Biopharm, 27, 45, 10.1023/A:1020630712388 Derendorf H, Garret ER. Pharmako-kinetik Einführung in die Theorie und Relevanz für die Arzneimitteltherapie. Stuttgart, Germany: Wiss. Verl-Ges; 1987. p. 110–1 [in German]. Schaffazick, 2002, Caracterização e estudo de estabilidade de suspensões de nanocápsulas e de nanoesferas poliméricas contendo diclofenaco, Acta Farm Bonaerense, 21, 99 Moffat, 2004 Floyd, 1998, Injectable emulsions and suspensions, vol. 3, 163 Mosqueira, 2001, Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules, Biomaterials, 22, 2967, 10.1016/S0142-9612(01)00043-6 Carter, 1977, Plasmodium of rodents, vol. 3, 359 Goldenberg, 1988, Quinine overdose: review of toxicity and treatment, Clin Cardiol, 11, 716, 10.1002/clc.4960111012 Newton, 1999, Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure, Trans R Soc Trop Med Hyg, 93, 69, 10.1016/S0035-9203(99)90184-0 Gref, 1995, The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres, Adv Drug Deliv Rev, 16, 215, 10.1016/0169-409X(95)00026-4 Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int J Pharm, 307, 93, 10.1016/j.ijpharm.2005.10.010 Krishna, 2001, Population pharmacokinetics of intramuscular quinine in children with severe malaria, Antimicrob Agents Chemother, 45, 1803, 10.1128/AAC.45.6.1803-1809.2001 Fang, 2004, Lipid nano/submicron emulsions as vehicles for topical flurbiprofen delivery, Drug Deliv, 11, 97, 10.1080/10717540490280697 Roten-Rutishauser, 2006, Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques, Environ Sci Technol, 40, 4353, 10.1021/es0522635 Chambers, 2007, Long circulation nanoparticles via adhesion on red blood cells: mechanism and extended circulation, Exp Biol Med, 232, 958 Soler, 2007, Interaction of erythrocytes with magnetic nanoparticles, J Nanosci Nanotechnol, 7, 1069, 10.1166/jnn.2007.423